Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
Critical Care, doi:10.1186/s13054-020-03117-9
Background: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak is spreading worldwide. To date, no specific treatment has convincingly demonstrated its efficacy. Hydroxychloroquine and lopinavir/ ritonavir have potential interest, but virological and clinical data are scarce, especially in critically ill patients. Methods: The present report took the opportunity of compassionate use and successive drug shortages to compare the effects of two therapeutic options, lopinavir/ritonavir and hydroxychloroquine, as compared to standard of care only. The primary outcomes were treatment escalation (intubation, extra-corporeal membrane oxygenation support, or renal replacement therapy) after day 1 until day 28. Secondary outcomes included ventilator-free days at day 28, mortality at day 14 and day 28, treatment safety issues and changes in respiratory tracts, and plasma viral load (as estimated by cycle threshold value) between admission and day 7.
Abbreviations ICU: Intensive care unit; SAPS II: Simplified Acute Physiology Score II; SOFA: Sequential Organ Failure Assessment; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; ECMO: Extra-corporeal membrane oxygenation; IQR: Interquartile range; CT: Cycle threshold; RT-PCR: Reverse transcription polymerase chain reaction Authors' contributions ML, LH, RD, and AB collected the patient's data. ML and MD analyzed the patient's data and have written the manuscript. All authors contributed to drafting the manuscript or critically revising it for important intellectual content and approved the final version of the manuscript.
Ethics approval and consent to participate The Research Ethics Committee of Sorbonne University approved the project (CER 2020-36). Oral information about this retrospective analysis was given to patients or relatives.
Consent for publication Not applicable
Competing interests Martin Dres received fees from Lungpacer (expertise, lectures). A Demoule reports personal fees from Medtronic; grants, personal fees, and non-financial support from Philips; personal fees from Baxter; personal fees from Hamilton; personal fees and non-financial support from Fisher & Paykel; grants from French Ministry of Health; personal fees from Getinge; grants and personal fees from Respinor; and grants and non-financial support from Lungpacer, outside the submitted work. The other authors have no conflicts of interest to declare.
Alhazzani, Møller, Arabi, Loeb, Gong, Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19), Intensive Care Med
Bhatraju, Ghassemieh, Nichols, Kim, Jerome et al., Covid-19 in critically ill patients in the Seattle region -case series, N Engl J Med
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavirritonavir in adults hospitalized with severe Covid-19, N Engl J Med
Chu, Cheng, Hung, Wong, Chan et al., Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax
Corman, Landt, Kaiser, Molenkamp, Meijer et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Euro Surveill
Cummings, Baldwin, Abrams, Sd, Meyer et al., Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Horby, Landray, None
Keyaerts, Vijgen, Maes, Neyts, Van Ranst, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochem Biophys Res Commun
Nguyen, Dolladille, Drici, Fenioux, Alexandre et al., Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization Pharmacovigilance Database
Romanelli, Smith, Hoven, Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity, Curr Pharm Des
Roques, Thiberville, Dupuis-Maguiraga, Lum, Labadie et al., Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection, Viruses
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review, JAMA
Taccone, Gorham, Vincent, Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base, Lancet Respir Med
Touret, De Lamballerie, Of chloroquine and COVID-19, Antivir Res
Von Elm, Altman, Egger, Pocock, Gøtzsche et al., Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, BMJ
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Lu, Li, Chen, Chen et al., Clinical course and outcomes of 344 intensive care patients with COVID-19, Am J Respir Crit Care Med
Wu, Chen, Cai, Xia, Zhou et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med
Yang, Yu, Xu, Shu, Xia et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study, Lancet Respir Med